Özgür Özyılkan

Akademik Profiller

1. 1
   GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patientsLung Cancer
   2020
2. 2
   Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, Palliative Care, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)Journal of Cancer Education
   2020
3. 3
   Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapyCancer Research
   2020
4. 4
   Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational studyJournal of Oncology Pharmacy Practice
   2020
5. 5
   nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast CancerClinical Breast Cancer
   2020
6. 6
   nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2-metastatic breast cancerAnnals of Oncology
   2020
7. 7
   Addition of taxanes to combination chemotherapy in distal intestinal gastric cancer is more beneficial than proximal ones: A multicenter retrospective study of Turkish Oncology GroupJournal of B.U.ON.
   2019
8. 8
   Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in TurkeyJournal of Thoracic Oncology
   2019
9. 9
   Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyThe Lancet
   2019
10. 10
    Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialThe Lancet
    2019

Yayın listesi ORCID kaydından alındı.